Nonsubstantive Change Justification

Change Request 0920-1310_12.11.25_final.docx

[NCEZID] Public Health Laboratory Testing for Emerging Antibiotic Resistance and Fungal Threats

Nonsubstantive Change Justification

OMB: 0920-1310

Document [docx]
Download: docx | pdf

Change Request


Public Health Laboratory Testing for Emerging Antibiotic Resistance and Fungal Threats (OMB No. 0920-1310, Exp. Date 12/31/2027)



Summary

The proposed changes to the Public Health Laboratory Testing for Emerging Antibiotic Resistance and Fungal Threats package are 1) adding a new data collection instrument for data that is to be collected in REDCap for participating jurisdictions (Attachment 3h), 2) wording changes to two existing data collection forms to comply with current Executive Orders (Attachment 3f and 3g) , and 3) wording changes that enhance the clarity of the questions/instructions as well as the removal of questions that are no longer relevant (Attachment 3a, 2d, 2f, 2m, 2o, and 2s), and 4) the removal of two instruments that are no longer being collected ( Attachment 2n and 2r).


Attachments

  1. Attachment 3a_AR Lab Network Annual Report of Testing Methods for Carbapenemase_producing Organisms

  2. Attachment 3f_AR Lab Network Alert and Monthly Data Report Form for Neisseria gonorrhoeae

  3. Attachment 3g_AR Lab Network DAART data elements for Neisseria gonorrhoeae

  4. Attachment 3h_Implementation of new HL7 messages—IT Initial Set up for Dermatophyte Reporting

  5. Attachment 2d_I.4- HAIAR WHOLE GENOME SEQUENCING (WGS) OF GRAM-NEGATIVE AR THREATS IN JURISDICTION- Annual Evaluation and Performance Measurement Report

  6. Attachment 2f_I.6- CARBAPENEMASE-PRODUCING ORGANISM (CPO) SCREENING IN JURISDICTION- Annual Evaluation and Performance Measurement Report

  7. Attachment 2m_I.13- ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) OF INVASIVE HAEMOPHILUS INFLUENZAE (H. INFLUENZAE) IN JURISDICTION- Annual Evaluation and Performance Measurement Report

  8. Attachment 2n_I.14- MYCOPLASMA GENTALIUM (MG)- Annual Evaluation and Performance Measurement Report

  9. Attachment 2o_I.15- MOLECULAR Mtb TESTING- Annual Evaluation and Performance Measurement Report

  10. Attachment 2r_I.18- HEALTHCARE WASTEWATER-BASED SURVEILLANCE - Annual Evaluation and Performance Measurement Report

  11. Attachment 2s_I.19- COMMUNICATION AND COORDINATION OFACTIONABLE EPI LAB DATA IN JURISDICTION- Annual Evaluation and Performance Measurement Report

Effect of Proposed Changes on Currently Approved Instruments


Attachment 3a AR Lab Network Annual Report of Testing Methods for Carbapenemase_producing Organisms

Type of Change 

Itemized Changes / Justification 

Impact to Burden 

Removal

Questions:

  1. Record ID (label as State_monthyear, ex: AK_032021)

  2. Does your lab utilize CDC's MicrobeNet?

  3. If no, please describe the decision tree for AST in your lab

  4. Alternatively, if no, you may upload any decision trees or workflow for AST in your lab

  5. MBL screen method (select all that apply)

  6. If other MBL method, please specify

  7. If using an immunochromatography test, which brand are you using?

  8. Report which state samples are sent to for WGS analysis.


Justification: No longer needed for collection from jurisdictions.

Decrease in burden 

Addition

Questions:

  1. If yes, please describe which WGS (wet-lab) protocols are validated and verified under CLIA standards (e.g., DNA extraction, library preparation, MiSeq sequencing)?

  2. Are your bioinformatic protocols validated and verified under CLIA standards?

  3. If yes, please describe which bioinformatic tools and/or pipelines are validated and verified under CLIA standards?

  4. If other, please specify

  5. Is HAI/AR WGS conducted via a sequencing core facility that also supports WGS for other programs/pathogens?

  6. If other, please specify.

  7. Number of MiniSeq instruments available for use

  8. Number of MiSeq DX instruments available for use

  9. If other, please specify.

  10. Are your bioinformatics supported through a contracted vendor/partner?

  11. If other, please specify.



Justification: Added to completely capture different protocols and tools being used by laboratories for while genome sequencing.

Increase in burden 

Attachment 3f AR Lab Network Alert and Monthly Data Report Form for Neisseria gonorrhoeae

Revision

  1. Patient’s Sex


Justification: Replaced gender with sex to comply with Executive Order


No change to burden 

Attachment 3g AR Lab Network DAART data elements for Neisseria gonorrhoeae

Revision

  1. Patient’s Sex


Justification: Replaced gender with sex to comply with Executive Order


No change to burden 

Attachment 3h Implementation of new HL7 messages—IT Initial Set up for Dermatophyte Reporting

Addition

Questions:

  1. Record ID

  2. ARLN isolate or REDCap ID

  3. ARLN specimen id

  4. ARLN PHL State

  5. Public health laboratory name

  6. REDCap reporting date

  7. CDC use only - REDCap reporting date

  8. CDC use only - Days since created (Calculation)

  9. CDC use only - REDCap last updated date

  10. Clinical sample or Isolate

  11. Specimen type

  12. Specimen collection date

  13. Specimen received date

  14. Healthcare facility of origin state or territory

  15. Healthcare facility of origin zip code

  16. Healthcare facility of origin name

  17. Healthcare facility of origin id

  18. Submitter specimen id

  19. Submitter facility state or territory

  20. Submitter facility zip code

  21. Submitter facility name

  22. Submitter facility id

  23. Patient ID

  24. Patient date of birth

  25. Patient's age

  26. Patient age unit

  27. Patient's sex

  28. Patient's race

  29. Race Other

  30. Patient ethnicity

  31. Patient's county code of residence

  32. Patient's county of residence

  33. Patient's state or territory of residence

  34. Patient's country of residence

  35. Did your lab perform antimicrobial-resistant dermatophyte testing?

  36. Species identified by your lab

  37. Date the species identification was performed by your lab

  38. Date the species identified by your lab was reported to the submitter

  39. Amphotericin b MIC

  40. Other amphotericin b MIC

  41. Date of amphotericin b MIC

  42. Date amphotericin b MIC results reported

  43. Anidulafungin MIC

  44. Other anidulafungin MIC

  45. Date of anidulafungin MIC

  46. Date of anidulafungin MIC results reported

  47. Caspofungin MIC

  48. Other caspofungin MIC

  49. Date of caspofungin AFST

  50. Date caspofungin MIC results reported

  51. Ibrexafungerp MIC

  52. Other ibrexafungerp MIC

  53. Date of ibrexafungerp MIC

  54. Date ibrexafungerp MIC reported

  55. Fluconazole MIC

  56. Other fluconazole MIC

  57. Date of fluconazole MIC

  58. Date flucoazole MIC reported

  59. Isavuconazole MIC

  60. Other isavuconazole MIC

  61. Date of isavuconazole MIC

  62. Date isavuconazole MIC results reported

  63. Itraconazole MIC

  64. Other itraconazole MIC

  65. Date of itraconazole MIC

  66. Date itraconazole MIC results reported

  67. Micafungin MIC

  68. Other micafungin MIC

  69. Date micafungin MIC

  70. Date micafungin MIC results reported

  71. Posaconazole MIC

  72. Other posaconazole MIC

  73. Date of posaconazole MIC

  74. Date posaconazole results reported

  75. Voriconazole MIC

  76. Other voriconazole MIC

  77. Date of voriconazole MIC

  78. Date voriconazole MIC results reported

  79. Ciclopirox MIC

  80. Other ciclopirox MIC

  81. Date of ciclopirox MIC

  82. Date ciclopirox MIC results reported

  83. Ravuconazole MIC

  84. Other ravuconazole MIC

  85. Date of ravuconazole MIC

  86. Date ravuconazole MIC results reported

  87. Rezafungin MIC

  88. Other rezafungin MIC

  89. Date of rezafungin MIC

  90. Date rezafungin MIC results reported

  91. Ketoconazole MIC

  92. Other ketoconazole MIC

  93. Date of ketoconazole MIC

  94. Date ketoconazole MIC results reported

  95. Luliconazole MIC

  96. Other luliconazole MIC

  97. Date of luliconazole MIC


  1. Date luliconazole MIC results reported

  2. Oteseconazole MIC

  3. Other oteseconazole MIC

  4. Date of oteseconazole MIC

  5. Date oteseconazole MIC results reported

  6. Manogepix MIC

  7. Other manogepix MIC

  8. Date of manogepix MIC

  9. Date manogepix MIC results reported

  10. Griseofulvin MIC

  11. Other griseofulvin MIC

  12. Date of griseofulvin MIC

  13. Date griseofulvin MIC reported

  14. Terbinafine MIC

  15. Other terbinafine MIC

  16. Date of terbinafine MIC

  17. Date terbinafine MIC reported

  18. Flucytosine MIC

  19. Other flucytosine MIC

  20. Date of flucytosine MIC

  21. Date flucytosine MIC reported

  22. Isolate forwarded?

  23. Date isolate forwarded

  24. PHL where the isolate was forwarded

  25. PHL name where the isolate was forwarded

  26. Did your lab perform WGS on this isolate?

  27. Date isolate was whole genome sequenced

  28. WGS ID

  29. SRR number

  30. WGS comments

  31. Any comments from your lab?

  32. Do you want MDB to delete this record from your dataset?

  33. Is this a record update for a DAART record that cannot be resubmitted via HL7?


Justification: This is a new data collection instrument that is intended to be collected in REDCap and HL7 messaging. This burden remains unchanged as this is already represented in the original time burden for Implementation of new HL7 messages – Initial set up.



Increase in burden by 8 hours for updates to HL7 reporting including additional testing, or LIMS re-validation.

Attachment 2d_I.4- HAIAR WHOLE GENOME SEQUENCING (WGS) OF GRAM-NEGATIVE AR THREATS IN JURISDICTION- Annual Evaluation and Performance Measurement Report

Revision

  1. Proportion of sequencing attempts for prioritized isolates received (i.e., CPOS, as defined in the latest General Guidance for Whole Genome Sequencing of Healthcare-Associated Infection/Antibiotic Resistant Pathogens in State and Local Public Health Laboratories) that passed quality control (QC) in accordance with CDC criteria:

    1. Numerator: Number of prioritized isolates that passed QC following first sequencing attempt (see guidance for sequencing priorities and QC thresholds)

    2. Denominator: Total number of sequencing attempts for prioritized isolates including all failed sequencing)

    3. Calculated: Percent of prioritized isolates tested by WGS that passed QC within first sequencing attempt



  1. Number and type of prioritized isolates (i.e., CPOs, as defined in the latest General Guidance for Whole Genome Sequencing of Healthcare-Associated Infection/Antibiotic Resistant Pathogens in State and Local Public Health Laboratories) tested by WGS associated with a known epidemiological investigation

    1. Number of prioritized organisms tested by WGS

    2. Type of prioritized organisms tested by WGS



  1. Median number and range from date of sequencing completion to recording the HAI WGS ID and NCBI or SRR-accession number in LIMS:ID to REDCap alerts records or AIMS DAART platform via HL7 2.5.1 messages or DHQP CSV upload:

    1. Median (in days)

    2. Range (in days)



Justification: Modified language of existing data elements

No change to burden

Addition

  1. Number of prioritized isolates stratified by priority category (i.e., CPOs, as defined in the latest General Guidance for Whole Genome Sequencing of Healthcare-Associated Infection/Antibiotic Resistant Pathogens in State and Local Public Health Laboratories) tested by WGS:

a. Total number of CRAB carrying Class A, Class B, or blaOXA-48-like carbapenemase genes tested by WGS

b. Total number of Carbapenemase-producing/carbapenemase-gene positive CRPA tested by WGS

c. Total number of Carbapenemase-producing/carbapenemase-gene positive CRE tested by WGS

Justification: Added because this element requires 3 data sources and will give us an indicator to monitor distribution of funds across CPO organisms, to improve prospective guidance/training products, and to better assist PHL programs with technical assistance.

No change to burden

Attachment 2f_I.6- CARBAPENEMASE-PRODUCING ORGANISM (CPO) SCREENING IN JURISDICTION- Annual Evaluation and Performance Measurement Report

Addition

  1. Total number of swabs tested for CPOs:

    1. Cepheid

    2. CRAB colonization screening

    3. Culture-based screening (excluding CRAB)

Justification: New data element needed.

No changes to burden

Attachment 2m_I.13- ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) OF INVASIVE HAEMOPHILUS INFLUENZAE (H. INFLUENZAE) IN JURISDICTION- Annual Evaluation and Performance Measurement Report

Revision

  1. Proportion of isolates with AST results reported to CDC-Bacterial Meningitis Laboratory (CDC-BML) yearly:

    1. Numerator: Number of isolates with AST results reported to CDC yearly

    2. Denominator: Number of HI isolates received for testing at AR Lab Network

    3. Calculated: Percentage of isolates with AST results reported to CDC yearly

  2. Number of isolates with AST results reported to CDC-Bacterial Meningitis Laboratory (CDC-BML) yearly (out of up to 500)

  3. Proportion of isolates transported to CDC-BML yearly

    1. Numerator: Number of viable isolates transported to CDC or in CDC posession

    2. Denominator: Total number of HI isolates tested at AR Lab Network

    3. Calculated: Percent of isolates transported to CDC yearly

Justification: Modified language of existing data elements

No changes to burden

Attachment 2n_I.14- MYCOPLASMA GENTALIUM (MG)- Annual Evaluation and Performance Measurement Report

Removal

Justification: Instrument is no longer being collected

Reduction in burden of 1 hour

Attachment 2o_I.15- MOLECULAR Mtb TESTING- Annual Evaluation and Performance Measurement Report

Addition

  1. Number and percentage or reports issued within 11 days of receipt or identification if performing CLIA-compliant testing

Justification: This addition is a passive data element and may not be included in REDCap/CAMP for data entry. However, we are including it as optional for recipients who choose to report.

No changes to burden

Attachment 2r_I.18- HEALTHCARE WASTEWATER-BASED SURVEILLANCE - Annual Evaluation and Performance Measurement Report

Removal

Justification: Instrument is no longer being collected


Reduction in burden of 1 hour

Attachment 2s_I.19- COMMUNICATION AND COORDINATION OFACTIONABLE EPI LAB DATA IN JURISDICTION- Annual Evaluation and Performance Measurement Report

Revision

  1. Median number and range from receipt of CRE, CRPA, CRAB and Candida isolates to communication of final testing results to submitting laboratory (report each pathogen separately):

    1. Median (in days)

    2. Range (in days)

Justification: Clarifies that each pathogen should be reported separately as opposed to median and range in aggregate across the four pathogens.

No changes to burden


Change in Annualized Burden Hours

Two performance measure instruments (Attachment 2n and 2r) and are no longer being collected and thus need to be deleted. This will reduce the overall burden of the package by 2 hours. Additionally, Attachment 3h will increase the burden package by 8 hours for updates to HL7 reporting, including additional testing, or LIMS re-validation. We have also reevaluated the burden of IT maintenance for HL7 message updates. Respondents will only need to complete this once per year as opposed to four times a year, as described in the original package. Due to this change, burden for IT maintenance has decreased by 32 burden hours. This will take the package from 57, 872 burden hours to 57,846 hours.



Updated Burden Table


 

Attachment 

Type of Respondents 

 

Form name 

 

Number of Respondents 

Average Number of Responses per Respondent 

Average Burden Per Response (in hours) 

Total Burden (in hours) 

2a 

Public Health Laboratories 

I.1 – ROUTINE TESTING BY GENERA IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

57 

10/60 

10 

2b 

Public Health Laboratories 

I.2- EXPANDED DRUG SUSCEPTIBILITY TESTING (ExAST) IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

10/60 

2c 

Public Health Laboratories 

I.3- CANDIDA SPECIES IDENTIFICATION IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

57 

10/60 

10 

2d 

Public Health Laboratories 

I.4- HAIAR WHOLE GENOME SEQUENCING (WGS) OF GRAM-NEGATIVE AR THREATS IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

Up to 57 

10/60 

10 

2e 

Public Health Laboratories 

I.5- C. AURIS COLONIZATION SCREENING IN JURISDICTION-Annual Evaluation and Performance Measurement Report 

Up to 57 

10/60 

10 

2f 

Public Health Laboratories 

I.6- CARBAPENEMASE-PRODUCING ORGANISM (CPO) SCREENING IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

Up to 57 

10/60 

10 

2g 

Public Health Laboratories 

I.7- AZOLE RESISTANCE IN CLINICAL ASPERGILLUS FUMIGATUS ISOLATES- Annual Evaluation and Performance Measurement Report 

20/60 

2h 

Public Health Laboratories 

I.8- N. GONORRHOEAE WHOLE GENOME SEQUENCING (WGS)- Annual Evaluation and Performance Measurement Report 

10/60 

2i 

Public Health Laboratories 

I.9- GONOCOCCAL (GC) ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

20/60 

2j 

Public Health Laboratories 

I.10- WHOLE GENOME SEQUENCING (WGS) OF S. PNEUMONAIE -Annual Evaluation and Performance Measurement Report 

20/60 

2k 

Public Health Laboratories 

I.11- CLOSTRIDIOIDES DIFFICILE (C. DIFFICLE) TESTING IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

20/60 

2l 

Public Health Laboratories 

I.12- ANTIFUNGAL RESISTANT TINEA DERMATOPHYTES -Annual Evaluation and Performance Measurement Report 

3  

20/60 

2m 

Public Health Laboratories 

I.13- ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) OF INVASIVE HAEMOPHILUS INFLUENZAE (H. INFLUENZAE) IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

20/60 








2o 

Public Health Laboratories 

I.15- MOLECULAR Mtb TESTING- Annual Evaluation and Performance Measurement Report 

Up to 20 

10/60 

2p 

Public Health Laboratories 

I.16- C. AURIS WHOLE GENOME SEQUENCING (WGS) IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

Up to 57 

10/60 

10 

2q 

Public Health Laboratories 

I.17- MONITORIING CRE CRPA IN COMPANION ANIMALS TO FROM HUMANS-Annual Evaluation and Performance Measurement Report 

Up to 2 

20/60 

 







2s 

Public Health Laboratories 

I.19- COMMUNICATION AND COORDINATION OFACTIONABLE EPI LAB DATA IN JURISDICTION- Annual Evaluation and Performance Measurement Report 

57 

10/60 

10 

2t 

Public Health Laboratories 

I.20- CHARACTERIZATION OF THE CLINICAL LABORATORY NETWORK IN JURISDICTION-Annual Evaluation and Performance Measurement Report 

57 

10/60 

10 

2u 

Public Health Laboratories 

I.21 NEISSERIA GONORRHOEAE ETEST FOR SHARP 

17 

20/60 

3a 

Public Health Laboratories 

AR Lab Network Annual Report of Testing Methods for Carbapenemase-producing Organisms 

57 

114 

3b 

Public Health Laboratories 

AR Lab Network Monthly Data Report Form for Carbapenemase-producing Organisms 

57 

1302 

20/60 

24,738 

3c 

Public Health Laboratories 

AR Lab Network Alert Report Form for Carbapenemase-producing Organisms  

57 

214 

3/60 

610 

3d 

Public Health Laboratories 

AR Lab Network Alert and Monthly Data Report Form for Candida 

Up to 57 

1671 

20/60 

31,749 

3e 

Public Health Laboratories 

AR Lab Network Form for Phylogenetic Tree-level Mycotics Reporting 

Up to 57 

30 

6/60 

171 

3f 

Public Health Laboratories 

AR Lab Network Alert and Monthly Data Report Form for Neisseria gonorrhoeae 

17 

93 

6/60 

158 

3g 

Public Health Laboratories 

AR Lab Network DAART data elements for Neisseria gonorrhoeae 

50 

10/60 

33 

NA 

Public Health Laboratories 

HL7 Messages updates-IT Maintenance  

32  

1

20/60 

11 

NA 

Public Health Laboratories 

Implementation of new HL7 messages—IT Initial Set up (may include 3b 3d, 3f, 3g, 3h) 

11 

132 

N/A

Public Health Laboratories

Updates to HL7 reporting including additional testing, or LIMS re-validation.

8

1

1

8

NA 

Public Health Laboratories 

CSV files updates for Carbapenemase-producing organisms-IT Maintenance  

24 

24 

 

Total 

 

 

 

 

 

57,846






File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorSwaray, Masiray (CDC/NCEZID/DHQP/OD) (CTR)
File Modified0000-00-00
File Created2026-01-07

© 2026 OMB.report | Privacy Policy